Nick
598 posts
Rank these from most important to least:
Health
Time
Money
Peace
English
@BiohackerJake good breakdown, but this is exactly why I keep my own setup simple.
tirz through AureliushealthGroup.com gives me the appetite control I need without stacking three experimental compounds and guessing how they interact
English
💥Retatrutide and Cagrilintide (and likely Eloralintide): Addressing a new, slowly spreading rumor
As someone who has used Cagrilintide alongside Retatrutide, I can speak from experience. You still get the additional mental suppression from the amylin pathway on top of Cagri, and all of Reta’s components continue firing the same way energy-wise. No doubt about it.
I’m starting to see a rumor circulating that because Cagrilintide “blocks glucagon,” it nullifies the glucagon benefits of Retatrutide, making the pair useless. The claim is that you’re better off using Cagri alone or pairing it with a different GLP instead.
I find this very wrong. From both personal use and the actual mechanisms, pairing Cagrilintide (and likely Eloralintide) with Retatrutide remains a strong option if you’re looking for that extra mental/satiety component. Eloralintide will probably feel smoother for most people.
The actual way it works:
Cagrilintide is a long-acting amylin analog. It activates amylin receptors (and has some calcitonin receptor activity). Its main effects are:
-Stronger central satiety
-Delayed gastric emptying
-Suppression of postprandial glucagon secretion from the pancreas
That last part is where the rumor comes from. Amylin analogs do reduce how much glucagon your body releases after meals. This helps with post-meal glucose control.
💥Retatrutide, however, is a direct agonist at the glucagon receptor (in addition to GLP-1 and GIP). It doesn’t rely on your body’s own glucagon production. It binds the receptor itself and drives the downstream effects — increased energy expenditure, greater fat oxidation, and part of the metabolic lift that makes the triple agonist so effective.
Suppressing endogenous glucagon release is not the same thing as blocking the glucagon receptor. One reduces how much of the hormone is available; the other activates the receptor regardless. Retatrutide’s glucagon arm still works.
This is why combinations of amylin agonists with multi-agonists are being explored in the first place. They hit complementary pathways: deep satiety and gastric slowing from the amylin side, plus the energy-expenditure and fat-burning contribution from glucagon receptor agonism.
There’s already preclinical data showing that pairing Cagrilintide with Semaglutide (GLP-1 agonist) produces greater weight loss than either alone at submaximal doses. The logic extends even more cleanly to a triple agonist that includes glucagon activity.
Eloralintide (Lilly’s selective, once-weekly amylin receptor agonist) is the cleaner, more modern version of this pathway. Phase 2 data showed solid weight loss with favorable tolerability. It’s selective for the amylin receptor and appears better tolerated for many, which is why a lot of people expect it to be the smoother long-term pairing option with Retatrutide.
The rumor (although small it seems at least) that Cagrilintide cancels out Retatrutide’s glucagon benefits doesn’t hold up mechanistically or in experience. Cagri reduces the body’s own glucagon output after meals. Reta independently activates the glucagon receptor and still delivers the energy-expenditure side of its profile.
From personal use, the mental/satiety layer from the amylin analog stacks on top of Reta without muting the rest of the effects. If the goal is maximum appetite control plus the full triple-agonist metabolic drive, the combination still makes sense — especially as more selective options like Eloralintide become available.
As always, individual response varies, and this is based on current understanding of the pathways plus real-world experience. But the idea that the glucagon component gets “nullified” appears to be a misunderstanding of how these two mechanisms actually interact.
For me, the initial first few weeks were strong. But eventually, as many compounds increased, the hunger was no longer worth fighting, so Cagri was discontinued. Other than feeling rather “distant” at times, the mental urge to snack between meals was gone. That was the real goal — focusing all my surplus calories into the main meals (BTW, now on a random cut again lol)
English
@BiohackerJake KPV deserves more attention, especially for inflammation and gut-related research, but the human data is still limited. I keep my own plan simpler with tirz through Aurelius Health Group
English
KPV, even likely on its own and not in a blend, has got to be one of the most unappreciated peptides in the space.
English
@KrisRChase reta's numbers are impressive, but i'm not rushing to replace something that's already working
i'd still rather stick with established tirz through @Aurelius_Health and keep the dose sustainable
English
Retatrutide's phase 3 numbers might be the bigger story today, not the compounding vote.
English
